Characterization of the immune cell infiltration landscape in myxofibrosarcoma to aid immunotherapy

Front Immunol. 2022 Jul 22:13:916915. doi: 10.3389/fimmu.2022.916915. eCollection 2022.

Abstract

Myxofibrosarcoma (MFS) is a highly malignant subtype of soft tissue sarcoma, accounting for 5% of cases. Immunotherapy guided by immune cell infiltration (ICI) is reportedly a promising treatment strategy. Here, MFS samples (n = 104) from two independent databases were classified as ICI clusters A/B/C and gene clusters A/B/C. Then, a close relationship between ICI and gene clusters was established. We found that the features of these clusters were consistent with the characteristics of immune-inflamed tumors (cluster C), immune-desert tumors (cluster B), and immune-excluded tumors (cluster A). Moreover, cluster C was sensitive to immunotherapy. Finally, an independent ICI score was established to predict the therapeutic effect, which has prospects for application in guiding immunotherapy during clinical practice.

Keywords: ICI; MFS; TME; immunotherapy; prognosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers, Tumor / genetics
  • Fibrosarcoma* / genetics
  • Fibrosarcoma* / therapy
  • Humans
  • Immunotherapy
  • Prognosis
  • Tumor Microenvironment*

Substances

  • Biomarkers, Tumor